Connecticut is home to a vibrant biotechnology sector that fosters innovation in areas such as drug development, medical diagnostics, and advanced therapies. Companies in this industry are involved in various specializations, creating products that address pressing health challenges, from cancer treatments to precision medicines. This fertile ground not only focuses on therapeutic developments but also emphasizes the importance of biotechnology in enhancing public health through diagnostics and vaccines. As the need for innovative solutions escalates, Connecticut's companies are poised to play a pivotal role in shaping the future of healthcare and biotechnology at large.

This list features 19 noteworthy biotechnology companies based in Connecticut, ranging from small startups to established firms. Located primarily in cities like New Haven and Branford, these companies were founded between 2000 and 2022 and specialize in fields such as cancer immunotherapy, molecular diagnostics, and cardiac research. With employee counts varying from fewer than 10 to over 200, each company demonstrates a strong commitment to addressing unmet medical needs and advancing the biotechnology sector in meaningful ways.

Continue reading to discover the top biotechnology companies in Connecticut.

Top 19 Biotechnology Companies in Connecticut

1. Simcha Therapeutics

• Website: simchatx.com
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $40.0M, January 2022
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: simcha-therapeutics

Simcha Therapeutics is a biotechnology company based in New Haven, Connecticut, founded in 2018. The company specializes in developing novel immunotherapies aimed at treating cancer. Their primary focus is on engineered cytokines, which are proteins that play a crucial role in regulating the immune system. One of their most advanced programs is ST-067, an innovative immunotherapy that targets IL-18BP, a decoy receptor that hinders immune response in the tumor microenvironment. This approach represents a new class of treatment that seeks to enhance the body's natural immune response against cancer. Simcha Therapeutics has attracted significant investment, securing $40 million in Series B funding in January 2022, which underscores the interest in their research and development efforts. The company is committed to transforming scientific discoveries into effective therapies that offer hope to cancer patients.

2. EvolveImmune Therapeutics

• Website: evolveimmune.com
• Ownership type: Venture Capital
• Headquarters: Branford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, October 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: evolveimmune-therapeutics

EvolveImmune Therapeutics, based in Branford, Connecticut, is a biotechnology firm that specializes in the development of precision cancer medicines. Founded in 2020, the company is dedicated to creating innovative immunobiologics and T cell engagers aimed at enhancing anti-cancer immunity. Their research focuses on overcoming challenges associated with CD8 T cell exhaustion within the tumor microenvironment, which is crucial for effective cancer treatment. EvolveImmune's pipeline includes several promising programs, such as EVOLVE-104 and EVOLVE-105, targeting various solid tumors and B cell malignancies. The company has recently raised $37 million in funding, which will support their ongoing research and development efforts. EvolveImmune's commitment to advancing cancer therapies positions it as a relevant player in the biotechnology sector, particularly in the field of immuno-oncology.

3. Normunity

• Website: normunity.com
• Ownership type: Private Equity
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $75.0M, January 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: normunity

Normunity is a biotechnology firm based in New Haven, Connecticut, founded in 2020. The company is dedicated to developing precision medicines and innovative cancer immunotherapies. By leveraging proprietary platforms, Normunity aims to uncover novel mechanisms that disrupt normal immune responses in cancer, thereby creating a new class of treatments known as immune normalizers. Their primary customers include cancer patients and healthcare providers seeking advanced therapeutic options. Normunity collaborates closely with the Yale School of Medicine, particularly with the Lieping Chen lab, to enhance their drug discovery efforts. The company has recently raised $75 million in Series B funding, which underscores its growth potential and commitment to addressing the challenges in cancer immunotherapy.

4. LAM Therapeutics

• Website: lamtherapeutics.com
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Latest funding: $40.0M, February 2016
• Founded year: 2013
• Headcount: 1-10
• LinkedIn: lam-therapeutics

LAM Therapeutics, based in Guilford, Connecticut, is a biotechnology firm established in 2013. The company is dedicated to developing breakthrough therapeutics aimed at treating cancer and rare diseases. Utilizing cutting-edge technologies, LAM Therapeutics focuses on precision medicine, with specific programs targeting lymphangioleiomyomatosis, B-cell non-Hodgkin lymphoma, and acute myeloid leukemia. Their drug candidates, including LAM-001, LAM-002, and LAM-003, have advanced into clinical trials, showcasing their commitment to addressing unmet medical needs. The company has successfully raised $40 million in funding to support its initiatives, reflecting investor confidence in its innovative approach and potential for growth in the biotechnology sector.

5. Kleo Pharmaceuticals Inc.

• Website: kleopharmaceuticals.com
• Ownership type: Corporate
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, January 2021
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: kleo-pharmaceuticals-inc.

Kleo Pharmaceuticals Inc. is a pharmaceutical company based in New Haven, Connecticut, established in 2015. The company is dedicated to developing innovative drug candidates aimed at addressing unmet medical needs in various therapeutic areas, including neuroscience, immunology, and oncology. Kleo Pharmaceuticals is currently conducting clinical trials for several conditions, such as obsessive-compulsive disorder (OCD), epilepsy, and spinal muscular atrophy (SMA). Their approach combines internal research and development with licensed intellectual property from notable institutions and companies, enhancing their drug development capabilities. As of January 2021, Kleo Pharmaceuticals secured $20 million in funding, which underscores their potential for growth and innovation in the biotechnology field. The company is committed to advancing science and improving patient outcomes through their focused research efforts.

6. BioXcel, LLC

• Website: bioxcel.com
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Employee distribution: India 90%, United States (USA) 10%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn: bioxcel-corporation

BioXcel, LLC, based in Guilford, Connecticut, is a biopharmaceutical company founded in 2005. The company specializes in developing transformative medicines by leveraging advanced artificial intelligence technology. BioXcel is particularly focused on addressing significant unmet medical needs in the fields of neuroscience and immuno-oncology. Their flagship product, IGALMI™ (dexmedetomidine), is an FDA-approved sublingual film designed for the acute treatment of agitation associated with schizophrenia and bipolar disorders. This product underscores BioXcel's commitment to improving patient outcomes. The company operates through its AI platform, EvolverAI, which enhances the efficiency of drug discovery and development processes. By combining human expertise with cutting-edge technology, BioXcel aims to accelerate the timeline for bringing new therapies to market, ultimately expanding the pipeline of potentially life-saving drugs.

7. Cybrexa Therapeutics

• Website: cybrexa.com
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $25.0M, March 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: cybrexa-therapeutics

Cybrexa Therapeutics, founded in 2017 and based in New Haven, Connecticut, is a biotechnology company dedicated to developing innovative cancer therapeutics. The firm specializes in peptide-drug conjugates, utilizing its proprietary alphalex technology platform to improve the delivery of anti-cancer agents directly to tumor cells. This approach aims to enhance treatment efficacy while minimizing side effects associated with traditional therapies. Cybrexa's pipeline includes promising candidates like CBX-12, which is currently in Phase 2 clinical trials for ovarian cancer after demonstrating a 40% response rate in earlier studies. The company has attracted significant venture capital, securing $25 million in its latest funding round in March 2021, which supports its ongoing research and development efforts. Cybrexa is committed to advancing treatment options for various solid tumors, including breast and colorectal cancers, and is led by a team of experienced professionals in the life sciences sector.

8. Imbrium Therapeutics

• Website: imbriumthera.com
• Ownership type: Private
• Headquarters: Stamford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: imbrium-therapeutics

Imbrium Therapeutics L.P., based in Stamford, Connecticut, is a clinical-stage biopharmaceutical company founded in 2018. The company is dedicated to advancing medical science through the development of important new therapeutics aimed at serious medical conditions. Imbrium operates within the biopharmaceutical industry, focusing on areas such as oncology, central nervous system disorders, and non-opioid pain management. Their pipeline includes investigational therapies like Tinostamustine, which is in Phase II trials for oncology, and Sunobinop, currently in Phase I trials for alcohol use disorder and other indications. As a subsidiary of Purdue Pharma L.P., Imbrium is positioned to leverage resources and expertise to enhance their drug development efforts. They actively seek collaborations with both commercial and academic partners to further their mission of addressing unmet patient needs.

9. Bexorg, Inc.

• Website: bexorg.com
• Ownership type: Private
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: bexorg-inc

Bexorg, Inc. is a biotechnology firm based in New Haven, Connecticut, founded in 2021. The company specializes in neuroscience research, aiming to revolutionize the understanding of brain diseases and enhance drug discovery processes. Bexorg has developed a proprietary whole-brain perfusion model, which allows researchers to manipulate and record cellular activity in intact brains for extended periods. This innovative approach overcomes the limitations of traditional cell cultures and organoids, providing a more accurate platform for studying brain function and developing therapies. Bexorg's technology has been validated through extensive research, including over 800 brain runs, and has been featured in several high-profile publications. Their clientele includes researchers and pharmaceutical companies, indicating a strong presence in the biotechnology sector focused on neurological health.

10. AVS Bio

• Website: avsbio.com
• Ownership type: Private Equity
• Headquarters: Norwich, Connecticut, United States (USA)
• Employee distribution: United States (USA) 98%, Spain 2%
• Latest funding: January 2023
• Founded year: 1961
• Headcount: 201-500
• LinkedIn: avsbio

AVS Bio, based in Norwich, Connecticut, is a biotechnology company founded in 1961. Initially known as SPAFAS, the company has evolved into a prominent producer of Specific Pathogen Free (SPF) eggs and related laboratory products. These products are essential for the development and manufacture of vaccines and therapeutics in both human and animal health markets. AVS Bio emphasizes quality and biosecurity, ensuring that their SPF eggs meet stringent standards required for vaccine production. The company operates over 40 production houses and has produced over one billion SPF eggs since its inception. In 2022, AVS Bio became an independent company after 30 years as a subsidiary of Charles River Laboratories, allowing it to focus on expanding its offerings and capabilities in the immunology sector. Their product range includes primary chicken embryo cells, IgY antibodies, and various diagnostic testing services, all of which support biologic development and manufacturing.

11. Propria LLC

• Website: propriabio.com
• Ownership type: Venture Capital
• Headquarters: Branford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $121,000, December 2019
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: propria-llc

Propria LLC, established in 2018 and based in Branford, Connecticut, is a biotechnology firm dedicated to advancing cardiac research. The company specializes in cardiac contractility testing and the development of engineered heart tissues (hEHTs). Their services cater to pharmaceutical and biotech companies, providing critical insights into the efficacy of new therapeutics through contractile profiling and disease modeling. Propria's innovative MyoPod™ platform enables the creation of human cardiac tissues that closely mimic adult human myocardium, offering a more realistic environment for testing. This capability is particularly valuable for understanding heart function and assessing the impact of various treatments. Founded by experts in cardiac physiology, Propria has established partnerships with numerous academic institutions and industry players, contributing to significant advancements in cardiac health research. The company received seed funding of $121,000 in December 2019, which supports its ongoing development and research initiatives.

12. Enrich Biosystems Inc.

• Website: enrichbiosystems.com
• Ownership type: Venture Capital
• Headquarters: Branford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: July 2021
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: enrich-therapeutics-inc

Enrich Biosystems Inc., founded in 2018 and based in Branford, Connecticut, is a biotechnology firm dedicated to enhancing cell therapy discovery and single-cell genomics. The company has developed a high-throughput cell discovery platform known as TROVO, which facilitates long-term time-lapse cellular imaging and behavior analysis. This platform is designed to simplify workflows for researchers by allowing them to create custom microwells for cell culture, enabling the observation of cell behavior under conditions that closely mimic their natural environment. Enrich's technology is particularly valuable for applications in cell therapy, rare cell isolation, and cell line development. The company primarily serves researchers and organizations in the life sciences sector, providing them with tools to improve their research and therapeutic development processes. Enrich Biosystems is also actively involved in industry initiatives, such as the Cell Manufacturing Research Initiative, which aims to advance the field of cell therapy.

13. 12-15 Molecular Diagnostics, Inc

• Website: 12-15mds.com
• Ownership type: Private
• Headquarters: East Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: 1215md

12-15 Molecular Diagnostics, Inc. is a biotechnology firm based in East Haven, Connecticut, founded in 2016. The company specializes in rapid diagnostic testing solutions aimed at infectious diseases and water quality. Their primary product, Veralize, is a portable testing device that provides results in under ten minutes, making it a practical option for healthcare providers, water treatment companies, and individual consumers. The technology behind Veralize employs advanced carbon-based nanomaterials for the detection of pathogens and contaminants in various fluids, including saliva and water. The company has participated in clinical trials, achieving a 98% accuracy rate for COVID-19 tests, which were part of a study funded by the National Institute of Health. 12-15 Molecular Diagnostics is committed to innovation and collaboration, striving to enhance public health and safety through their testing solutions.

14. QCDx

• Website: qcd-x.com
• Ownership type: Private
• Headquarters: Farmington, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.7M, May 2025
• Founded year: 2017
• Headcount: 1-10
• LinkedIn: qcdx-llc

QCDx, based in Farmington, Connecticut, is a medical diagnostics company that specializes in cancer treatment optimization. Founded in 2017, the company has developed advanced technologies aimed at detecting and profiling rare circulating tumor cells (CTCs) in blood samples. Their flagship products, the RareScope™ system and MultiFluor™ probes, provide oncologists with real-time insights that can significantly enhance treatment strategies. QCDx primarily serves healthcare providers and research institutions, focusing on improving cancer patient outcomes. The company has also received funding, with a reported amount of $1.7 million in May 2025, which supports its ongoing research and development efforts in the field of cancer diagnostics.

15. Project Farma (PF)

• Website: projectfarma.com
• Ownership type: Corporate
• Headquarters: Shelton, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: March 2025
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: projectfarma

Project Farma (PF) is a consulting firm based in Shelton, Connecticut, founded in 2016. The company specializes in biomanufacturing strategy and execution, providing essential services to clients in the life sciences and biotechnology sectors. Their offerings include facility builds, tech transfers, validation, and regulatory compliance, which are vital for companies looking to optimize their manufacturing processes. Project Farma partners with a variety of organizations, including startups, established corporations, universities, and hospitals, demonstrating their broad impact across the industry. They have developed expertise in advanced therapy manufacturing, particularly in cell and gene therapy, and have created a comprehensive playbook for this area. Their commitment to quality and compliance ensures that they meet the stringent requirements of the biotechnology field, making them a valuable player in the sector.

16. NGT BioPharma Consultants

• Website: ngtbiopharmaconsultants.com
• Ownership type: Private
• Headquarters: East Lyme, Connecticut, United States (USA)
• Employee distribution: United States (USA) 58%, United Kingdom (UK) 11%, Canada 11%, Other 21%
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: ngtbiopharmaconsultants

NGT BioPharma Consultants, founded in 2018 and based in East Lyme, Connecticut, is a consulting firm dedicated to drug development and advanced technologies. With a team of experienced professionals, they provide tailored consulting services to pharmaceutical and biotech companies at various stages of drug development. Their offerings include regulatory strategy, quality compliance, and specialized consulting for pediatric drug development. NGT BioPharma Consultants collaborates with a wide range of clients, from start-ups to established biopharmaceutical companies, helping them navigate the intricate processes involved in bringing new drugs to market. Their Pediatric Center of Excellence highlights their commitment to addressing the unique challenges of developing safe and effective medications for children, an area that requires specialized knowledge and regulatory understanding. By leveraging their extensive network of consultants, NGT BioPharma Consultants aims to enhance the efficiency and success of drug development programs.

17. Virscio

• Website: virscio.com
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: Saint Kitts and Nevis 51%, United States (USA) 49%
• Latest funding: January 2008
• Founded year: 2002
• Headcount: 51-200
• LinkedIn: rxgen

Virscio is a biomedical research company based in New Haven, Connecticut, founded in 2002. The company specializes in providing advanced preclinical services to biotechnology and pharmaceutical firms. Their mission is to accelerate therapeutic innovation and improve research and development efficiency by developing and applying advanced preclinical models, methods, and technologies. Virscio's unique approach involves the use of nonhuman primates, specifically African green monkeys, to create predictive models that better reflect human biology. This focus on translational research aims to reduce the time, cost, and risk associated with bringing new therapies to clinical trials. Virscio operates with a commitment to high ethical standards and animal welfare, ensuring that their research practices align with industry regulations. They have established a strong reputation for generating definitive, actionable data that supports the development of therapies across various therapeutic areas, including ophthalmology, central nervous system disorders, and gene therapy.

18. Wren Laboratories

• Website: wrenlaboratories.com
• Ownership type: Private
• Headquarters: Branford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: wren-laboratories

Wren Laboratories, founded in 2013 and based in Branford, Connecticut, is a private diagnostics laboratory focused on molecular cancer diagnostics. The company specializes in advanced liquid biopsy tests, utilizing mRNA technology to provide oncologists and biopharma companies with essential diagnostic information. Their flagship products, NETest and PROSTest, are designed to enhance cancer management by offering insights into tumor activity and treatment responses. Wren Laboratories operates as a CLIA-certified lab, ensuring compliance with rigorous quality standards. The company has a strong emphasis on research and development, with a pipeline that includes assays for various cancer types beyond neuroendocrine and prostate cancers. Their innovative approach has garnered attention in the medical community, with their tests being utilized in clinical settings and supported by numerous peer-reviewed studies. Wren Laboratories aims to transform cancer diagnostics and improve patient outcomes through their cutting-edge technologies.

19. Canopy Life Sciences

• Website: hellocanopy.com
• Ownership type: Private
• Headquarters: Danbury, Connecticut, United States (USA)
• Employee distribution: United States (USA) 76%, India 14%, Romania 5%, Other 4%
• Founded year: 2000
• Headcount: 201-500
• LinkedIn: framework-solutions-inc-

Canopy Life Sciences, based in Danbury, Connecticut, is a private consulting firm established in 2000. With a workforce of around 224 employees, the company focuses on providing a range of services tailored to the life sciences sector. Their expertise includes regulatory affairs, medical affairs, content innovation, and global recruiting, all aimed at assisting clients in the pharmaceutical, biotech, and medical device industries. Canopy's team is equipped to help organizations navigate the intricate processes involved in drug development and ensure compliance with regulatory standards. Their global presence extends to locations in the UK, India, and Romania, reflecting their commitment to serving a broad client base. By offering on-demand expertise and technology solutions, Canopy Life Sciences positions itself as a key partner for companies striving to bring innovative products to market efficiently.

Biotechnology Insights: Key Companies in Connecticut

Want to Find More Biotechnology Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!